BAX · Insider Trading
Baxter International Inc.
Every open-market purchase and sale reported by BAX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Andrew P. Hider | President and CEO | F | −54,276 | −$1.39M |
| 2026-09-03 | James Teaff | President, CCS | F | −750 | −$19.11K |
| 2026-09-03 | Julie Foster | President, Front Line Care | F | −2,098 | −$53.92K |
| 2026-06-03 | James Teaff | President, CCS | F | −321 | −$6.00K |
| 2026-06-03 | Steven P. Wallace | President, Adv. Surgery | F | −153 | −$2.86K |
| 2026-06-03 | Anita A Zielinski | SVP, Interim CFO, CAO & Cntrlr | A | +13,426 | — |
| 2026-05-07 | William A. Ampofo II | Director | A | +12,836 | — |
| 2026-05-07 | Jeffrey A Craig | Director | A | +12,836 | — |
| 2026-05-07 | Michael R. McDonnell | Director | A | +12,836 | — |
| 2026-05-07 | David Brent Shafer | Director | A | +12,836 | — |
| 2026-05-07 | Patricia Morrison | Director | A | +12,836 | — |
| 2026-05-07 | Nancy M Schlichting | Director | A | +12,836 | — |
| 2026-05-07 | Amy McBride Wendell | Director | A | +12,836 | — |
| 2026-05-07 | David S. Wilkes | Director | A | +12,836 | — |
| 2026-03-10 | Joel T. Grade | EVP and CFO | F | −8,153 | −$144.23K |
| 2026-03-10 | Reazur Rasul | EVP,Group Pres,Healthcare | F | −12,674 | −$224.20K |
| 2026-03-10 | David S. Rosenbloom | EVP and General Counsel | F | −6,620 | −$117.11K |
| 2026-03-10 | Maria Cecilia Soriano | Group Pres., ITT & Pharma. | F | −2,848 | −$50.38K |
| 2026-03-10 | Anita A Zielinski | SVP, CAO and Controller | F | −1,932 | −$34.18K |
| 2026-03-03 | Anita A Zielinski | SVP, CAO and Controller | A | +30,864 | — |
| 2026-03-03 | Joel T. Grade | EVP and CFO | A | +42,735 | — |
| 2026-03-03 | David S. Rosenbloom | EVP and General Counsel | MIXED | +25,373 | −$26.31K |
| 2026-03-03 | Maria Cecilia Soriano | Group Pres., ITT & Pharma. | MIXED | +21,890 | −$36.47K |
| 2026-03-03 | Reazur Rasul | EVP,Group Pres,Healthcare | F | −1,614 | −$31.78K |
| 2026-03-03 | Cynthia Carlisle | Executive Vice President, CHRO | A | +29,677 | — |
| 2026-03-03 | Andrew P. Hider | President and CEO | A | +201,804 | — |
| 2026-02-18 | Michael R. McDonnell | Director | A | +1,811 | — |
| 2026-02-11 | Joel T. Grade | EVP and CFO | MIXED | +21,360 | −$198.70K |
| 2026-02-11 | Reazur Rasul | EVP,Group Pres,Healthcare | MIXED | +13,181 | −$125.38K |
| 2026-02-11 | David S. Rosenbloom | EVP and General Counsel | MIXED | +11,830 | −$113.54K |
| 2026-02-11 | Maria Cecilia Soriano | Group Pres., ITT & Pharma. | MIXED | +1,355 | −$19.95K |
| 2025-12-16 | Jeanne K Mason | EVP, Chief HR Officer | F | −650 | −$12.45K |
| 2025-12-03 | Joel T. Grade | EVP and CFO | F | −8,288 | −$158.14K |
| 2025-09-04 | James W Borzi | EVP,Chief Supply Chain Officer | F | −1,848 | −$44.67K |
| 2025-09-04 | Joel T. Grade | EVP and CFO | A | +102,712 | — |
| 2025-09-04 | Andrew P. Hider | President and CEO | A | +368,050 | — |
| 2025-09-04 | Alok Sonig | EVP,Group President,Pharma | F | −3,191 | −$77.13K |
| 2025-08-21 | David Brent Shafer | Director | F | −31,337 | −$762.43K |
| 2025-06-04 | David S. Rosenbloom | EVP and General Counsel | F | −16,548 | −$488.99K |
| 2025-05-08 | Jeffrey A Craig | Director | A | +7,183 | — |
| 2025-05-08 | William A. Ampofo II | Director | A | +7,183 | — |
| 2025-05-08 | Patricia Morrison | Director | A | +7,183 | — |
| 2025-05-08 | Stephen N. Oesterle | Director | A | +7,183 | — |
| 2025-05-08 | Stephen H Rusckowski | Director | A | +7,183 | — |
| 2025-05-08 | Nancy M Schlichting | Director | A | +7,183 | — |
| 2025-05-08 | Cathy R Smith | Director | A | +7,183 | — |
| 2025-05-08 | Amy McBride Wendell | Director | A | +7,183 | — |
| 2025-05-08 | David S. Wilkes | Director | A | +7,183 | — |
| 2025-03-10 | James W Borzi | EVP,Chief Supply Chain Officer | MIXED | +6,727 | −$115.61K |
| 2025-03-10 | Joel T. Grade | EVP and CFO | MIXED | +25,232 | −$152.60K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jose E Almeida | Chairman, CEO, President | 568,565 | $14.17M |
| Andrew P. Hider | President and CEO | 518,447 | $12.92M |
| Joel T. Grade | EVP and CFO | 271,674 | $6.77M |
| Jeanne K Mason | EVP, Chief HR Officer | 199,853 | $4.98M |
| Heather Knight | EVP, Chief Operating Officer | 177,362 | $4.42M |
| David S. Rosenbloom | EVP and General Counsel | 138,216 | $3.44M |
| Alok Sonig | EVP,Group President,Pharma | 128,219 | $3.20M |
| Reazur Rasul | EVP,Group Pres,Healthcare | 125,557 | $3.13M |
| Christopher A. Toth | EVP, Group Pres, Kidney Care | 105,186 | $2.62M |
| Maria Cecilia Soriano | Group Pres., ITT & Pharma. | 75,045 | $1.87M |
| David Brent Shafer | Interim CEO and Chair | 72,804 | $1.81M |
| James W Borzi | EVP,Chief Supply Chain Officer | 71,948 | $1.79M |
| Steven P. Wallace | President, Adv. Surgery | 70,128 | $1.75M |
| Anita A Zielinski | SVP, Interim CFO, CAO & Cntrlr | 59,714 | $1.49M |
| Amy McBride Wendell | Director | 44,235 | $1.10M |
| Patricia Morrison | Director | 42,386 | $1.06M |
| David S. Wilkes | Director | 37,076 | $923.93K |
| Stephen N. Oesterle | Director | 35,847 | $893.31K |
| Nancy M Schlichting | Director | 34,994 | $872.05K |
| William A. Ampofo II | Director | 30,375 | $756.95K |
| James Teaff | President, CCS | 30,370 | $756.82K |
| Cathy R Smith | Director | 30,345 | $756.20K |
| Cynthia Carlisle | Executive Vice President, CHRO | 29,677 | $739.55K |
| Julie Foster | President, Front Line Care | 29,164 | $726.77K |
| Jeffrey A Craig | Director | 23,662 | $589.66K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BAX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.